The One Biopharmaceutical

The One Biopharmaceutical is a clinical-stage biotechnology company with operations in Beijing and Taiwan, specializing in the development of innovative therapies for oncology and metabolic liver diseases. The company's oncology division focuses on next-generation biotherapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs) designed to modulate the tumor microenvironment. Its lead oncology candidate, T1B1, is a bifunctional fusion protein targeting PD-L1 and TGF-beta currently in clinical development for solid tumors. Additionally, the company is advancing a pipeline for metabolic disorders, notably featuring Ganwei, a GNMT inducer for the treatment of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. By leveraging proprietary technology platforms, The One Biopharmaceutical aims to address significant unmet medical needs through multi-targeted therapeutic approaches.